Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
BiCAR
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
- NCT04703686 ↗
- Completed
- The Lymphoma Academic Research Organisation
- Focused
We haven't built an HCP commentary report on BiCAR (glofitamab plus obinutuzumab in relapsed/refractory diffuse large B-cell lymphoma after CAR-T therapy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BiCAR so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Diffuse Large B-Cell Lymphoma Refractory; Refractory Indolent Adult Non-Hodgkin Lymphoma; Refractory Transformed B-cell Non-Hodgkin Lymphoma; Refractory Primary Mediastinal Large B-Cell Cell Lymphoma; Refractory Mantle Cell Lymphoma
- Interventions
- Obinutuzumab; RO7082859
- Arms
- Obinutuzumab + RO7082859 · Experimental
- Enrollment
- 67
- Primary outcomes
- Overall Survival
- Sponsor
- The Lymphoma Academic Research Organisation
- Start
- Mar 30, 2021
- Primary completion
- Jan 10, 2023
- Results posted
- No
- Registry record
- NCT04703686 · updated Mar 16, 2026
Publications
linked from the registry- Cartron G, Chaillol I, Houot R, Al Tabaa Y, Le Bras F, Ysebaert L, Choquet S, Jardin F, Bay JO, Gros FX, Morschhauser F, Rossi C, Gastinne T, Thieblemont C, Joris M, Ricard L, Regny C, La Rochelle LD, Feugier P, Marcais A, Ould-Ammar R, Tarte K, Laurent C, Sesques P. Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm. J Hematol Oncol. 2026 Jul 1. doi: 10.1186/s13045-026-01816-4. Online ahead of print. PubMed 42393723